PMID- 23640946
OWN - NLM
STAT- MEDLINE
DCOM- 20140130
LR  - 20221207
IS  - 1898-4002 (Electronic)
IS  - 1896-1126 (Linking)
VI  - 58
IP  - 1
DP  - 2013
TI  - Comparative efficacy of exenatide versus insulin glargine on glycemic control in 
      type 2 diabetes mellitus patients inadequately treated with metformin 
      monotherapy.
PG  - 38-43
LID - 10.2478/v10039-012-0078-7 [doi]
AB  - PURPOSE: Comparative efficacy of exenatide versus insulin glargine primarily on 
      glucemic control, and secondarily on body mass index (BMI), lipid profile and 
      blood pressure, in type 2 diabetes mellitus (T2DM) patients suboptimally treated 
      with metformin monotherapy. MATERIAL/METHODS: Forty-seven inadequately treated 
      T2DM patients on metformin assigned to exenatide (n=18) or insulin glargine 
      (n=29) for 26 weeks. Glycosylated hemoglobin (HbA1c), serum lipids, BMI, systolic 
      and diastolic blood pressure, and adverse events, including episodes of 
      hypoglycemia and gastrointestinal symptoms, were recorded. RESULTS: Either 
      treatment had a similar favorable mean reduction in HbA1c. However, more patients 
      in exenatide group achieved HbA1c </= 7% at the 26th week compared with insulin 
      glargine group (p=0.036). Insulin glargine group had significantly more episodes 
      of hypoglycemia compared with exenatide group (p=0.039). Gastrointestinal adverse 
      events were non-significantly higher in the exenatide group. A significantly 
      greater BMI reduction was observed in exenatide group, whereas BetaMuIota was not 
      altered in insulin glargine group. Total and LDL cholesterol (p=0.012), and 
      triglycerides (p=0.016) significantly decreased, whereas HDL cholesterol 
      increased (p=0.021) in the exenatide group, whereas only total cholesterol 
      decreased in insulin glargine group. Changes in systolic and diastolic blood 
      pressure were insignificant in both groups. CONCLUSIONS: Exenatide provided 
      similar reduction in HbA1c, but fewer episodes of hypoglycemia, compared with 
      insulin glargine. Exenatide had also a favorable effect on weight loss, although 
      more gastrointestinal adverse events. Exenatide may provide a justified 
      alternative in second line treatment of T2DM, but more trials are required to 
      elucidate its long-term safety and cost-effectiveness.
FAU - Karagianni, P
AU  - Karagianni P
AD  - Diabetes Centre, Second Propedeutic Medical Clinic, Aristotle University of 
      Thessaloniki, Ippokration Hospital, Thessaloniki, Greece.
FAU - Polyzos, S A
AU  - Polyzos SA
FAU - Kartali, N
AU  - Kartali N
FAU - Zografou, I
AU  - Zografou I
FAU - Sambanis, C
AU  - Sambanis C
LA  - eng
PT  - Clinical Trial
PT  - Comparative Study
PT  - Journal Article
PL  - Netherlands
TA  - Adv Med Sci
JT  - Advances in medical sciences
JID - 101276222
RN  - 0 (Blood Glucose)
RN  - 0 (Glycated Hemoglobin A)
RN  - 0 (Hypoglycemic Agents)
RN  - 0 (Insulin, Long-Acting)
RN  - 0 (Lipids)
RN  - 0 (Peptides)
RN  - 0 (Venoms)
RN  - 2ZM8CX04RZ (Insulin Glargine)
RN  - 9100L32L2N (Metformin)
RN  - 9P1872D4OL (Exenatide)
SB  - IM
MH  - Anthropometry
MH  - Blood Glucose/metabolism
MH  - Blood Pressure/drug effects
MH  - Body Mass Index
MH  - Diabetes Mellitus, Type 2/*drug therapy
MH  - Exenatide
MH  - Female
MH  - Glycated Hemoglobin/metabolism
MH  - Humans
MH  - Hypoglycemic Agents/*therapeutic use
MH  - Insulin Glargine
MH  - Insulin, Long-Acting/*therapeutic use
MH  - Lipids/blood
MH  - Male
MH  - Metformin/*therapeutic use
MH  - Middle Aged
MH  - Multivariate Analysis
MH  - Peptides/*therapeutic use
MH  - Prospective Studies
MH  - Treatment Outcome
MH  - Venoms/*therapeutic use
EDAT- 2013/05/04 06:00
MHDA- 2014/01/31 06:00
CRDT- 2013/05/04 06:00
PHST- 2013/05/04 06:00 [entrez]
PHST- 2013/05/04 06:00 [pubmed]
PHST- 2014/01/31 06:00 [medline]
AID - S1896-1126(14)60169-3 [pii]
AID - 10.2478/v10039-012-0078-7 [doi]
PST - ppublish
SO  - Adv Med Sci. 2013;58(1):38-43. doi: 10.2478/v10039-012-0078-7.